Insider · CIK 0001366265
Michael Richman
Files at NXTC (NextCure, Inc.). First filing -, latest -.
In brief
Michael Richman files SEC Form 4 as CEO, president and director at NXTC (NextCure, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Michael Richman has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 2 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jan 30, 2026 | NXTC NextCure, Inc. | AGrant or award Employee Stock Option (Right to Buy)derivative | +38,190 | $0.00 | $0 | 38,190 | Feb 3, 2026 |
| Jan 31, 2024 | NXTC NextCure, Inc. | AGrant or award Employee Stock Option (Right to Buy)derivative | +305,500 | $0.00 | $0 | 305,500 | Feb 1, 2024 |
Questions about Michael Richman
Answered from the filings on this page, as of the latest one.
Is Michael Richman buying or selling?
Michael Richman has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Michael Richman's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Michael Richman has 0.
Where does Michael Richman file Form 4?
Michael Richman has filed Form 4 at NXTC (NextCure, Inc.) as President & CEO. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.